Amgen is beefing up its inflammatory diseases portfolio with an agreement to buy US biopharma ChemoCentryx for roughly $3.7 billion. The deal gives Amgen access to...
21.04.2015
- ChemoCentryx, Inc, a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, has begun enrolling patients with non-resectable...
